Evidence map›Paper›PMID 40065708›Full record

ArticleZhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences2025

[

Tanlu Chu, Wei Zhang, Jingwen Chen, Zeyue Pan, Lingfeng Wang, Xiaoming Zhong, Fengmei Qiu, Zhen Huang

Abstract readEnglish Abstract
PubMed Full text at PMC Publisher
In one paragraph

Article in Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Tanlu ChuSchool of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou 310053, China. 651958476@qq.com.
Wei ZhangSchool of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou 310053, China.
Jingwen ChenSchool of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou 310053, China.
Zeyue PanSchool of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou 310053, China.
Lingfeng WangJinhua Academy of Zhejiang Chinese Medical University, Jinhua 321053, Zhejiang Province, China.
Xiaoming ZhongSchool of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou 310053, China.
Fengmei QiuSchool of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou 310053, China.
Zhen HuangSchool of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou 310053, China. huangzhen@zcmu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo investigate the effect of

methodsA CIRI rat model and a cell model were induced by middle cerebral artery occlusion (MCAO) in Sprague Dawley rats and oxygen glucose deprivation/reperfusion (OGD/R) in BV2 cells, respectively. The CIRI rat model was evaluated using the modified neurological severity score (mNSS), brain water content, and cerebral infarction volume after 1.5 h of ischemia followed by 72 h of reperfusion. Histopathological changes in the cortex and hippocampal CA1 region were observed with hematoxylin and eosin staining. Microglial polarization and NOD-like receptor thermal protein domain associated protein (NLRP) 3 inflammasome expression in the cortex were examined by immunofluorescence. BV2 cell viability was measured via MTT assay after treatment with ICCB and Nigericin. The expressions of NLRP3, ASC, caspase-1 proteins and inflammatory cytokines were detected with Western blotting in OGD/R treated BV2 cells (0.5 h OGD+24 h reperfusion) and in cells pretreated with Nigericin for 24 h.

resultsICCB treatment significantly improved neurological function, reduced cerebral infarct volume and brain water content, and mitigated pathological damage in the cortical and hippocampal CA1 regions of rats subjected to CIRI (all

conclusionsICCB exerts a protective effect against CIRI by mitigating neuroinflammation, through the reduction of M1 microglial polarization, promotion of M2 conversion, and suppression of the NLRP3/ASC/caspase-1 signaling pathway.

Indexed as

Brain IschemiaMicrogliaReperfusion InjuryAnimalsMaleNLR Family, Pyrin Domain-Containing 3 ProteinRatsRats, Sprague-DawleyNLR Family, Pyrin Domain-Containing 3 ProteinNlrp3 protein, ratCerebral ischaemia-reperfusion injuryInflammasomeIn vitro cultured calculus bovisMicrogliaNOD-like receptor thermal protein domain associated protein 3SD rats

Identifiers

PMID40065708
PMCPMC12176533

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.